Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
Twelve-month findings showed improvement in Composite Unified Huntington’s Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an expected decline of -0.92 points in propensity score-weighted natural history analyses of
